[The Journal] Weight-Loss Drugs Are Gobbling Up Small Town Budgets

A few years ago, GLP-1 drugs — the class of medications that includes Ozempic and Wegovy — transformed the conversation around obesity treatment. Municipal governments and small-town employers, eager to invest in worker wellness and get ahead of long-term healthcare costs, began adding these drugs to their employee health insurance plans.

The logic seemed straightforward: if employees lost weight with the help of these medications, the town would ultimately spend less on obesity-related conditions such as diabetes and heart disease. Local officials viewed the coverage as both a recruitment tool and a fiscally responsible long-term investment. At the time, relatively few employees were expected to use the drugs, keeping projected costs manageable.

What local finance officers failed to anticipate was how dramatically uptake would accelerate. As awareness of GLP-1 drugs spread and stigma around their use declined, enrollment in the benefit grew far beyond initial forecasts, sending insurance premiums to levels that small-town budgets simply were not built to absorb.

The town of Belchertown, Massachusetts, became one of the starkest examples of this phenomenon. When officials received their annual insurance renewal figures, the numbers were devastating. The town’s premium costs had surged dramatically, driven almost entirely by GLP-1 drug spending. A selectwoman who helped lead the town’s response described the bill as a shock that forced an immediate reassessment of the entire benefits structure.

Faced with a bill the town could not pay without cutting other services, officials were forced to make difficult decisions quickly. The process involved renegotiating terms with the insurance provider, exploring whether to scale back the GLP-1 benefit, and weighing the political and human consequences of removing a drug that employees had come to rely on for managing serious health conditions.

Belchertown’s experience highlighted a fundamental tension in public sector benefits management: the gap between the promise of innovative healthcare and the fiscal reality of a fixed local tax base. Unlike large corporations or state governments, small towns have almost no buffer to absorb sudden cost overruns without direct consequences for residents.

Belchertown is far from alone. Across the country, small municipalities that extended GLP-1 coverage are now grappling with the same math. The core problem is structural: GLP-1 drugs cost hundreds to over a thousand dollars per patient per month, and the drugs typically must be taken indefinitely to maintain their effects. For a self-insured town — one that pays claims directly rather than transferring all risk to an insurer — even a modest number of employees on these medications can blow a hole in the annual budget.

Many towns are now weighing a narrow set of options: require prior authorization so that only employees with documented medical need qualify; cap the annual drug benefit; shift a larger share of costs to employees through higher copayments; or drop GLP-1 coverage entirely. Each option carries political risk, since employees who have lost significant weight on these drugs strongly resist any rollback of coverage.

The episode exposes a broader vulnerability in the way American public employers manage healthcare. Small governments often lack the actuarial expertise and financial reserves to properly assess the risk of covering novel, high-cost therapies. As pharmaceutical innovation accelerates, the mismatch between cutting-edge treatments and the modest fiscal capacity of local government is likely to widen — leaving elected officials to make agonizing trade-offs between employee welfare and the town services that residents depend on every day.